The company presented three posters at AACR, two of which demonstrated insights from its circulating DNA monitoring in colorectal and bladder cancers.
Natera outlined its work with pharmaceutical firms to use the Signatera assay, while Luminex was bullish about its growing molecular diagnostics business.
Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
Using an integrated omics approach, researchers identified non-muscle invasive bladder cancer subtypes, along with pathways that are frequently altered in the disease.
The company believes the approach could allow researchers to profile tumor signaling pathways via blood or urine samples, similar to how ctDNA analysis is used.
In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.
Natera said that this research collaboration and others will help it clinically validate its circulating tumor DNA assay Signatera.
The company said the dramatic increase was driven by a one-time buy-out of patents related to colorectal cancer by Exact Sciences.
The study will perform next-generation sequencing on archival tumor tissue from 200 individuals with metastatic urothelial cancer.
American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.
A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.
Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.
In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.